RxDoctor Payments Data

Rosa Neno, DO

Internal Medicine · Bayonne, NJNPI 1407850894

Payments from drug & device makers

$4,856in general payments, 2019–2025

Across 307 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$612
  • AbbVie$490
  • Lilly USA, LLC$398
  • Pfizer$393
  • AstraZeneca$346
  • Amgen$269
  • plus $2K from 53 others

What the payments were for

  • Food & beverage$4,832100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,856 in reported general payments places this provider in the 85th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$202,867
Medicare patients
444
Services billed
2,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$84,729
LinzessLinaclotide65$60,057
JardianceEmpagliflozin55$46,655
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$43,419
Diclofenac Potassium23$41,354
XifaxanRifaximin12$39,412
FarxigaDapagliflozin Propanediol29$36,509
OxycontinOxycodone Hcl39$34,322
Lactulose11$29,756
JanuviaSitagliptin Phosphate27$29,247
CreonLipase/Protease/Amylase19$28,485
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate17$28,263
TrulicityDulaglutide23$27,941
ProliaDenosumab16$26,774
MounjaroTirzepatide12$22,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Synthroid$490$95,242174 claims
PfizerEliquis, Celebrex$393$91,93395 claims
Boehringer IngelheimJardiance, Tradjenta$77$67,99884 claims
Lilly USA, LLCTrulicity, Mounjaro$398$50,03935 claims
GSKTrelegy Ellipta, Breo Ellipta$612$47,76965 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$168$39,41212 claims
AstraZenecaFarxiga$346$36,50929 claims
MerckJanuvia, Dulera$77$32,71838 claims
AmgenProlia$269$26,77416 claims
Astellas Pharma US IncMyrbetriq$115$10,98424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Bayonne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →